Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 23, 2013 at 9:00 AM Eastern; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2013 beginning at 9:00 AM Eastern at the Sheraton Rockville Hotel, 920...
Emergent BioSolutions to Webcast Presentation at Bank of America Merrill Lynch 2013 Health Care Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas on May 16,...
Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it presented preclinical data on its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, at the 9th Annual Protein and...
Emergent BioSolutions Reports Financial Results for First Quarter 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the first quarter ended March 31,...
Emergent BioSolutions Participates in NATO Defense against Terrorism Workshop at the Counter Terror Expo in London
Emergent BioSolutions Inc. (NYSE:EBS) announced its participation in the Defence against Terrorism Programme of Work (DAT POW) workshop conducted by the North Atlantic Treaty Organization (NATO)...
Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody Day
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Credit Suisse First Annual Antibody Day in New York on May 10, 2013 at 9:30 AM...
Emergent BioSolutions to Acquire Healthcare Protective Products Division of Bracco Diagnostics Inc.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an asset purchase agreement to acquire the Healthcare Protective Products Division (HPPD) of Bracco Diagnostics Inc. in...
Emergent BioSolutions Announces Positive Preclinical Efficacy and PK Data for Its New Bispecific Adaptir Protein Therapeutic ES414 at AACR
Emergent BioSolutions Inc. (NYSE: EBS) today announced that two posters on the development of its lead bispecific ADAPTIRTM (Modular Protein Technology) molecule, ES414, were presented earlier this...
Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has presented data on ES210, one of its bispecific ADAPTIRTM (Modular Protein Technology) molecules, that is targeting autoimmune...
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab Based on Strong Patient Enrollment and Encouraging Early Clinical Data
Emergent BioSolutions Inc. (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy...
Emergent BioSolutions to Release First Quarter 2013 Financial Results and Conduct a Conference Call on May 2, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the first quarter 2013 on Thursday, May 2, 2013, after market...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2012
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31,...